Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Lan Wang.

Newcastle AuthorsTitleYearFull text
Duncan Miller
Tristan Reuillon
Dr Lauren Molyneux
Dr Tim Blackburn
Dr Noel Edwards
et al.
Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor2022
Islam Al-Khawaldeh
Dr Christine Basmadjian
Dr Cinzia Bordoni
Dr Suzannah Harnor
Amy Heptinstall
et al.
An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)2021
Lan Wang
Professor Nilanjan Chakraborty
Effects of the cold wall boundary on the flame structure and flame speed in premixed turbulent combustion2021
Daniel Wood
Svitlana Korolchuk
Dr Natalie Tatum
Lan Wang
Professor Jane Endicott
et al.
Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition2019
Stephanie Myers
Duncan Miller
Dr Lauren Molyneux
Dr Mercedeh Arasta
Dr Ruth Bawn
et al.
Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD42019
Christopher Coxon
Dr Suzannah Harnor
Dr Mathew Martin
Dr Benoit Carbain
Professor Bernard Golding
et al.
Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines2017
Dr Christopher Wong
Dr Ian Hardcastle
Christopher Matheson
Professor Herbie Newell
Dr Mangaleswaran Sivaprakasam
et al.
Structure-guided design of purine-based probes for selective Nek2 inhibition2017
Dr Gary Beale
Dr Emma Haagensen
Huw Thomas
Lan Wang
Charlotte Revill
et al.
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer2016
Lan Wang
Professor Herbie Newell
Professor Steve Wedge
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation2016
Dr Benoit Carbain
Dr Allyson Campbell
Dr Celine Cano
Professor Jane Endicott
Professor Bernard Golding
et al.
8-Substituted O-6-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode2014
Honorine Lebraud
Professor Bernard Golding
Elisa Meschini
Dr Celine Cano
Lan Wang
et al.
Anticancer agents targeted against cyclin-dependent kinase 2 (CDK2): Structure-based design of irreversible and reversible inhibitors2014
Dr Mathew Martin
Elisa Meschini
Lan Wang
Dr Regina Mora Vidal
Tristan Reuillon
et al.
Identification and characterization of an irreversible inhibitor of CDK22014
Dr Benoit Carbain
Christopher Coxon
Honorine Lebraud
Christopher Matheson
David Turner
et al.
2-arylamino-6-ethynylpurines as Potent Irreversible Inhibitors of the Mitotic Kinase Nek22012
Dr Sonja Baumli
Dr Alison Hole
Lan Wang
Professor Martin Noble
Professor Jane Endicott
et al.
The CDK9 Tail Determines the Reaction Pathway of Positive Transcription Elongation Factor b2012
Elisa Meschini
Professor Jane Endicott
Professor Bernard Golding
Dr Ian Hardcastle
Professor Herbie Newell
et al.
Design and synthesis of dual CDK2 and CDK7 inhibitors2010
Dr Nicola Johnson
Dr Johanne Bentley
Lan Wang
Professor Herbie Newell
Professor Craig Robson
et al.
Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells2010
Dr Francesco Marchetti
Dr Celine Cano
Professor Nicola Curtin
Professor Bernard Golding
Professor Roger Griffin
et al.
Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors2010
Dr Christopher Wong
Professor Roger Griffin
Dr Ian Hardcastle
Dr Julian Scott Northen
Lan Wang
et al.
Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated SN2 reactivity of 2,2,2-trifluoroethoxysulfonates2010
Huw Thomas
Dr Kappusamy Saravanan
Lan Wang
Mei Lin
Dr Julian Scott Northen
et al.
Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity2009
Professor Herbie Newell
Huw Thomas
Lan Wang
Dr Celine Roche
Dr Ian Hardcastle
et al.
[abstract] Preclinical in vitro and in vivo evaluation of the cyclin dependent kinase 2 inhibitor NU6102 and a water pro-drug NU63012008
Lan Wang
Professor Nicola Curtin
Professor Herbie Newell
Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked2008
Huw Thomas
Dr Christopher Calabrese
Michael Batey
Suzanne Kyle
Professor Herbie Newell
et al.
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial2007
Dr Francesco Marchetti
Kerry Louise Sayle
Dr Johanne Bentley
Emeritus Professor Bill Clegg
Professor Nicola Curtin
et al.
Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6- aminopyrimidine inhibitors of cyclin-dependent kinase 22007
Huw Thomas
Dr Christopher Calabrese
Professor Herbie Newell
Lan Wang
Professor Nicola Curtin
et al.
Identification of a PARP inhibitor for clinical trial: Preclinical studies2006
Professor Roger Griffin
Andrew Henderson
Professor Nicola Curtin
Professor Jane Endicott
Dr Ian Hardcastle
et al.
Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination2006
Professor Herbie Newell
Professor Roger Griffin
Richard Davison
Lan Wang
Professor Nicola Curtin
et al.
Effect of cell cycle inhibition on cisplatin-induced cytotoxicity2005
Professor Roger Griffin
Dr YuZhu Cheng
Professor Nicola Curtin
Professor Bernard Golding
Dr Ian Hardcastle
et al.
Potent CDK2 inhibitors generated using a variant of the cope elimination2005
Dr Allyson Campbell
Dr YuZhu Cheng
Lan Wang
Professor Nicola Curtin
Professor Bernard Golding
et al.
Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: A possible role for survivin down-regulation2005
Andrew Henderson
Dr YuZhu Cheng
Professor Nicola Curtin
Professor Bernard Golding
Professor Roger Griffin
et al.
Searching for potent CDK2 inhibitors using a variant of the Cope elimination2005
Dr Christopher Calabrese
Michael Batey
Professor Alan Calvert
Professor barbara Durkacz
Suzanne Kyle
et al.
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG143612004
Dr Christopher Calabrese
Professor Nicola Curtin
Suzanne Kyle
Huw Thomas
Lan Wang
et al.
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase2004
Dr Ian Hardcastle
Dr Christine Arris
Dr Johanne Bentley
Professor Nicola Curtin
Professor Jane Endicott
et al.
N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 22004
Professor Nicola Curtin
Lan Wang
Suzanne Kyle
Dr Christine Arris
Professor barbara Durkacz
et al.
Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells2004
Dr Veronique Mesguiche
Rachel Parsons
Dr Christine Arris
Dr Johanne Bentley
Professor Nicola Curtin
et al.
4-Alkoxy-2,6-diaminopyrimidine derivatives: Inhibitors of cyclin dependent kinases 1 and 22003
Dr Christopher Calabrese
Michael Batey
Huw Thomas
Professor barbara Durkacz
Lan Wang
et al.
Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies2003
Kerry Louise Sayle
Dr Johanne Bentley
Professor Alan Calvert
Dr YuZhu Cheng
Professor Nicola Curtin
et al.
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 22003
Dr Christopher Calabrese
Professor Nicola Curtin
Suzanne Kyle
Huw Thomas
Lan Wang
et al.
Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure2002
Dr Johanne Bentley
Dr Christine Arris
Professor Nicola Curtin
Professor Jane Endicott
Dr Ashleigh Gibson
et al.
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor2002
Professor Nicola Curtin
Dr Stephen Barton
Michael Batey
Dr Christopher Calabrese
Professor Alan Calvert
et al.
Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.2001
Lan Wang
Professor Nicola Curtin
Professor Herbie Newell
Tumor radiosensitization using TBI-361, an inhibitor of poly (ADP-ribose) polymerase (PARP)2001
Lan Wang
Suzanne Kyle
Alex White
Professor Alan Calvert
Professor Nicola Curtin
et al.
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines2000
Professor Nicola Curtin
Suzanne Kyle
Lan Wang
Professor barbara Durkacz
Professor Roger Griffin
et al.
Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors1999